Physician profile
Paul Williams
NPI 1306823992
$625.13
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $192 · 2021: $295 · 2022: $17.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $180.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.47 | 2021 | |
| Pfizer INC. | $68.24 | 2020-2021 | |
| Novo Nordisk INC | $52.09 | 2021 | |
| Amarin Pharma, INC. | $29.10 | 2020 | |
| Orexo US, INC. | $28.98 | 2019 | |
| Indivior INC. | $26.29 | 2019-2020 | |
| Kaleo, INC. | $25.55 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.81 | 2021 | |
| Alkermes, INC. | $17.21 | 2020 | |
| Eisai INC. | $15.27 | 2020 | |
| Sanofi Pasteur INC. | $13.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.54 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.